The threat of drug-resistant bacteria continues to grow — and so does our commitment to helping you combat this global issue. As a
leader in diagnostics for more than 50 years, we have made it our mission to innovate and advocate for better antibiotic stewardship.
Discover how Roche can help you bring insights and innovative solutions to your institution’s antibiotic stewardship program.
Antibiotics are an important treatment option, but their misuse is causing devastating impact.
We’re committed to helping you advance your antibiotic stewardship efforts.
Our long-term strategy to help improve patient lives includes:
Substantial investments in numerous assays that help clinicians make more effective treatment decisions using antibiotics or antivirals
Educational support for healthcare providers so they can successfully comply with new regulatory mandates
A deep-seated commitment to promote and implement principles of good antibiotic stewardship
Learn about Global AMR Challenge
Roche offers a broad portfolio of products which can enable better clinical decisions and therefore appropriate antibiotic use.
Click on the products below to learn more!
cobas® Liat® PCR System
Treat common infections with confidence at the earliest possible convenience.
Elecsys® BRAHMS PCT Assay
cobas® MRSA/SA | Cdiff Tests
Identify and contain healthcare-associated infections (HAIs).
Accuracy and speed that
support antibiotic stewardship
This CLIA-waived system is uniquely positioned to provide accurate, actionable results at the point of care. Whether results are positive or negative, you can confidently treat patients without the need to wait for confirmation.
Help determine if antibiotics are needed or if certain bacterial infections are resolving.
The Elecsys BRAHMS PCT solution aids in assessing the mortality risk of patients fighting sepsis and guiding antibiotic decision-making for patients with lower respiratory tract infections, like pneumonia, bronchitis, COPD and sepsis.5,6
Timely and cost-effective molecular solutions for improved HAI management
The cobas MRSA/SA and Cdiff tests provide provide excellent performance and broad coverage to increase confidence in HAI testing. Run on the fully automated cobas 4800 system, these assays may help your institution control infections and costs.
Want to learn more? Click on the webinar links below.
External links and resources to help you with your Antimicrobial Stewardship initiatives
References
1 Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/biggest-threats.html, accessed October 23, 2019
2 Centers for Disease Control and Prevention. “1 in 3 antibiotic prescriptions unnecessary.” CDC Newsroom. https://www.cdc.gov/antibiotic-use/stewardship-report/outpatient.htmll (accessed October 23, 2019).
3 IMS Health. Avoidable Costs in U.S. Healthcare. Danbury, CT: IMS Health; 2013.
4 Centers for Disease Control and Prevention. https://www.cdc.gov/hai/data/portal/index.html, accessed October 23, 2019
5 Elecsys BRAHMS PCT [package insert]. Indianapolis, IN: Roche Diagnostics; 2016.
6 Elecsys BRAHMS PCT antibiotic initiation and deescalation claims are pending 510(k) clearance.
COBAS, LIAT, ELECSYS and VIEWICS are trademarks of Roche.
© 2019 Roche Diagnostics, North America. All rights reserved.
